Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Regeneron's Lynozyfic Shows Deep Responses in AL Amyloidosis Trial

Regeneron Pharmaceuticals announced positive Phase 1/2 LINKER-AL2 trial results for Lynozyfic (linvoseltamab) monotherapy in adults with second-line-plus systemic AL amyloidosis. The BCMAxCD3 bispecific antibody demonstrated deep and rapid hematologic responses, with 100% of patients achieving a complete response (CR) at the highest tested dose (240 mg) and 71% at 80 mg. All patients achieved a very good partial response (VGPR) or better at 80 mg. Responses were rapid, with involved free light chains normalizing by day 15 and a median time to hematologic CR of 47 days. Significant improvements in renal (73%) and cardiac (50%) organ function were also observed. These results will be presented at ASCO 2026, and the Phase 2 portion with registrational intent is ongoing.

• Lynozyfic monotherapy achieved remarkable hematologic complete response (CR) rates in previously treated systemic AL amyloidosis patients. Specifically, 100% of patients in the 240 mg dose group (n=13) achieved a CR, and 71% (5 of 7) in the 80 mg dose group achieved a CR, with all patients in the lower-dose group achieving a very good partial response (VGPR) or better. These rates are notably higher than the 53% CR observed with the standard-of-care multi-drug combination in untreated patients, highlighting Lynozyfic's potential in a challenging patient population with no approved second-line options.
• The trial demonstrated rapid and deep reductions in involved free light chains (iFLC), which normalized by day 15, indicating swift destruction of plasma cells. Crucially, a majority of patients with organ involvement showed improvement in renal (73% of 11 patients) and cardiac (50% of 8 patients by biochemical response) function, with no patients experiencing major organ deterioration. This rapid and significant organ response is critical for AL amyloidosis patients who often face life-threatening organ dysfunction.
• Lynozyfic monotherapy exhibited a manageable safety profile. All patients experienced at least one treatment-emergent adverse event (TEAE), with 65% being Grade ≥3. The most common TEAEs were cytokine release syndrome (50%, all Grade <3), neutropenia (40%, 35% Grade 3/4), and infusion-related reactions (35%, all Grade <3). Infections occurred in 85% of patients (25% Grade ≥3) but were resolved. One patient discontinued due to AEs, and two deaths occurred, assessed as unrelated or in the context of cardiac amyloidosis.

Addressing the Unmet Need in Relapsed/Refractory AL Amyloidosis

Current treatment approaches for systemic AL amyloidosis face substantial challenges that limit therapeutic success and patient outcomes. Despite recent advances, significant gaps remain in addressing the complex pathophysiology and diverse clinical presentations of this rare plasma cell disorder. The heterogeneous nature of AL amyloidosis, combined with high treatment-related toxicity and limited therapeutic options for certain patient populations, continues to pose major obstacles for clinicians.

• High treatment-related mortality and toxicity — Treatment-related mortality reaches approximately 15% with high-dose chemotherapy and autologous stem cell transplantation, with significant toxicity from myeloablative chemotherapy including acute renal failure due to white blood cell lysis syndrome

• Incomplete organ function restoration — Despite successful reduction of light chains through chemotherapy, restoration of organ function remains highly variable and often incomplete, with organ damage continuing as the major source of mortality and morbidity

• Limited options for relapsed/refractory disease — No FDA-approved therapies exist specifically for patients with relapsed and/or refractory AL amyloidosis, with no established standard salvage regimen or optimal timing for treatment following daratumumab failure

• Diagnostic delays and complexity — AL amyloidosis is often diagnosed late due to diverse clinical presentations that mimic common medical conditions, requiring high clinical suspicion and precise classification that continues to pose significant challenges

• Poor cardiac prognosis — Nearly 80% of patients have cardiac involvement manifesting as heart failure, which carries particularly poor prognosis and represents the single most adverse prognostic feature

• Inadequate treatment for frail patients — Current unmet needs include effective treatment options for frail patients who cannot tolerate intensive therapies, highlighting the need for methods to reduce treatment-related toxicity

• Dose-response dilemma — Reducing chemotherapy dose in high-risk patients sacrifices treatment response, with overall response rates dropping from 75% in high-dose melphalan groups to 53% in intermediate-dose groups

LINKER-AL2: Efficacy and Safety of Lynozyfic in AL Amyloidosis

Recent clinical studies in AL amyloidosis demonstrate promising therapeutic advances across multiple treatment modalities. These investigations span from novel immunotherapies to established combination regimens, providing valuable insights into efficacy and safety profiles for this complex disease.

Lynozyfic's Broad Clinical Development Beyond AL Amyloidosis

Linvoseltamab (Lynozyfic) is primarily being developed for relapsed/refractory multiple myeloma (RRMM) rather than systemic amyloid light chain (AL) amyloidosis. The BCMA×CD3 bispecific antibody has received FDA approval for RRMM management and is being investigated in various clinical settings to optimize therapeutic outcomes.

Lynozyfic's Promise: Reshaping AL Amyloidosis Treatment

The recent announcement regarding linvoseltamab's positive Phase 1/2 LINKER-AL2 trial results in systemic AL amyloidosis marks a significant moment for patients grappling with this rare and devastating disease. Linvoseltamab, a bispecific antibody targeting BCMA and CD3, has already demonstrated its transformative potential in relapsed/refractory multiple myeloma, where it has shown deep and durable responses. Now, these new data suggest a similar, if not more profound, impact in AL amyloidosis.

The trial showcased remarkable efficacy, with 100% of patients achieving a complete response at the highest dose and 71% at 80 mg, alongside rapid normalization of involved free light chains. Crucially, significant improvements in renal and cardiac organ function were also observed. For AL amyloidosis, where progressive organ damage is a hallmark, such rapid and deep responses are paramount for preserving organ function and improving patient survival. This positions linvoseltamab to potentially become a groundbreaking, first-in-class BCMA-directed therapy for this indication, offering a much-needed off-the-shelf option.

However, the journey forward is not without considerations. While the efficacy is compelling, the safety profile of BCMA-directed bispecific antibodies is well-documented in multiple myeloma, including risks of cytokine release syndrome, neurotoxicity, and a high incidence of infections. These toxicities will require vigilant management, especially in a patient population that may already have compromised organ function due to amyloid deposition. Furthermore, as with any novel immunotherapy, the long-term durability of these responses and the full safety landscape in a larger AL amyloidosis cohort will need to be confirmed in ongoing registrational studies. The potential for mechanisms of resistance, such as antigen escape or T-cell exhaustion, also warrants ongoing monitoring to ensure sustained patient benefit. Despite these challenges, the data offers substantial hope for redefining the treatment paradigm for AL amyloidosis.